These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26357842)

  • 1. Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
    Jamieson C; Hasserjian R; Gotlib J; Cortes J; Stone R; Talpaz M; Thiele J; Rodig S; Pozdnyakova O
    J Transl Med; 2015 Sep; 13():294. PubMed ID: 26357842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
    Harrison CN; Schaap N; Vannucchi AM; Kiladjian JJ; Tiu RV; Zachee P; Jourdan E; Winton E; Silver RT; Schouten HC; Passamonti F; Zweegman S; Talpaz M; Lager J; Shun Z; Mesa RA
    Lancet Haematol; 2017 Jul; 4(7):e317-e324. PubMed ID: 28602585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High concordance in grading reticulin fibrosis and cellularity in patients with myeloproliferative neoplasms.
    Pozdnyakova O; Wu K; Patki A; Rodig SJ; Thiele J; Hasserjian RP
    Mod Pathol; 2014 Nov; 27(11):1447-54. PubMed ID: 24762543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.
    Paul B; Zhao Y; Loitsch G; Feinberg D; Mathews P; Barak I; Dupuis M; Li Z; Rein L; Wang E; Kang Y
    Cancer Med; 2020 Aug; 9(16):5869-5880. PubMed ID: 32628819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis.
    Pardanani A; Tefferi A; Masszi T; Mishchenko E; Drummond M; Jourdan E; Vannucchi A; Jurgutis M; Ribrag V; Rambaldi A; Koh LP; Rose S; Zhang J; Harrison C
    Br J Haematol; 2021 Oct; 195(2):244-248. PubMed ID: 34331348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis.
    Pardanani A; Tefferi A; Jamieson C; Gabrail NY; Lebedinsky C; Gao G; Liu F; Xu C; Cao H; Talpaz M
    Blood Cancer J; 2015 Aug; 5(8):e335. PubMed ID: 26252788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current and future role of fedratinib in the treatment of myelofibrosis.
    Ragheb M; Harrison CN; McLornan DP
    Future Oncol; 2020 Feb; 16(6):175-186. PubMed ID: 31971457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.
    Pardanani A; Harrison C; Cortes JE; Cervantes F; Mesa RA; Milligan D; Masszi T; Mishchenko E; Jourdan E; Vannucchi AM; Drummond MW; Jurgutis M; Kuliczkowski K; Gheorghita E; Passamonti F; Neumann F; Patki A; Gao G; Tefferi A
    JAMA Oncol; 2015 Aug; 1(5):643-51. PubMed ID: 26181658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis.
    Passamonti F; Lou Y; Chevli M; Abraham P
    Future Oncol; 2024; 20(17):1165-1174. PubMed ID: 37991002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis - an option beyond ruxolitinib.
    Saha C; Harrison C
    Expert Rev Hematol; 2022 Jul; 15(7):583-595. PubMed ID: 35787092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis.
    Verstovsek S; Talpaz M; Ritchie E; Wadleigh M; Odenike O; Jamieson C; Stein B; Uno T; Mesa RA
    Leukemia; 2017 Feb; 31(2):393-402. PubMed ID: 27479177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK6 Is a Therapeutic Target in Myelofibrosis.
    Dutta A; Nath D; Yang Y; Le BT; Mohi G
    Cancer Res; 2021 Aug; 81(16):4332-4345. PubMed ID: 34145036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Would you like to take some more ruxolitinib after your fedratinib?
    Ianotto JC
    Br J Haematol; 2024 Oct; 205(4):1253-1254. PubMed ID: 39143468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone marrow fibrosis during momelotinib or ruxolitinib therapy do not correlate with efficacy outcomes in patients with myelofibrosis.
    Oh ST; Verstovsek S; Gupta V; Platzbecker U; Devos T; Kiladjian JJ; McLornan DP; Perkins A; Fox ML; McMullin MF; Mead AJ; Egyed M; Mayer J; Sacha T; Kawashima J; Huang M; Strouse B; Mesa R
    EJHaem; 2024 Feb; 5(1):105-116. PubMed ID: 38406514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fedratinib: First Approval.
    Blair HA
    Drugs; 2019 Oct; 79(15):1719-1725. PubMed ID: 31571162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): a post-hoc analysis of molecular biomarkers in a phase 2 study.
    Pemmaraju N; Garcia JS; Potluri J; Harb JG; Sun Y; Jung P; Qin QQ; Tantravahi SK; Verstovsek S; Harrison C
    Lancet Haematol; 2022 Jun; 9(6):e434-e444. PubMed ID: 35576960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice.
    Debeurme F; Lacout C; Moratal C; Bagley RG; Vainchenker W; Adrian F; Villeval JL
    J Cell Mol Med; 2015 Nov; 19(11):2564-74. PubMed ID: 26176817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.